Methods are provided for treating a cancer characterized by the presence of a mutant allele of IDH1 / 2 comprising administering to a person in need thereof a compound described herein. Claim 1: A compound of formula (1) or a pharmaceutically acceptable salt, isotopologist or hydrate thereof, wherein: R¹ is optionally substituted C₄₋₆ carbocyclyl； each R² and R³ is independently selected from optionally substituted aryl or optionally substituted heteroaryl； R⁴ is alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl or optionally substituted heteroaralkyl；a. Ring a is a 4-6 member aromatic free ring with 0-1 extra heteroatoms selected from n or s, in which the ring a can be replaced by one or two r83099 groups；a. Each r83099 independent halo； - cf832323；-CN； -OR⁶；-N (R) -C (O) C₁₋₄ alkyl；a. Halogenated tar c83218d31832424；C₁₋₄ alkyl optionally substituted by -OR⁶ or -N (R⁶) ₂；-O-or8310o-n (r8310a) 832224, the substitute is halo；-SO N (R)-So832222 (lease No. c833213183)；-No. 8310； No. so8322； No. 8310；C₃₋₅ carbocyclyl optionally substituted by one or two R⁶ groups；-O - (carbocciillo c8332-833318326 was selectively replaced by one or two r8310 groups)；5-6 membered heteroaryl； -C₁₋₄-C (O) alkyl O-C₁₋₄ alkyl or -C (O) O-C₁₋₄ alkyl；or each R⁶ is independently H or C₁₋₃ alkyl.Se proporcionan métodos para tratar un cáncer caracterizado por la presencia de un alelo mutante de IDH1/2 que comprenden administrar a un individuo que lo necesita un compuesto descrito en la presente. Reivindicación 1: Un compuesto de fórmula (1) o una sal, tautómero isotopólogo o hidrato farmacéuticamente aceptable del mismo, en donde: R¹ es carbociclilo C₄₋₆ opcionalmente sustituido； cada R² y R³ se selecciona independientemente de arilo opcionalmente sustituido o heteroarilo opcionalmente sustituido； R⁴ es alquilo, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, aralquilo opcionalmente sustituido o heteroaralquilo opcionalment
